Drugs / IGM-7354
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05702424 | Jan 2023 → May 2024 | cancer | IGM Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGM-7354 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05702424 ↗ |
| Route | Intravenous | “IGM-7354 will be administered intravenously (IV).” NCT05702424 ↗ |